31 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those in this “Risk
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
property; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully
8-K
EX-99.1
44f3ixc0857 6lwn8pu6
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
2z5s eihkb
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
zzk5pip4 imbga94x0
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
5bwzag8wm9hp
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
xejjcxb0c6xevt
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
jeckp5zt56j8s6avj
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
m888v ef4pmujok
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
1n3oqz16y m3vt
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-99.1
uijahfe7z lcoc7u6j
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-99.1
bh6xb94b ptyb4vp
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
tfrzw
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
jwo6jshxwjiiz0
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
dd6b3ki0us0cn6vtzz
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
xjbywdg3ar4j2u elk
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am